MAPK15
MOLECULAR TARGETmitogen-activated protein kinase 15
MAPK15 (mitogen-activated protein kinase 15) is targeted by 29 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting MAPK15
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | alvocidib | 4.52 | 91 |
| 2 | foretinib | 4.34 | 76 |
| 3 | doramapimod | 4.06 | 57 |
| 4 | quizartinib | 3.99 | 53 |
| 5 | bms 387032 | 3.47 | 31 |
| 6 | tae 684 | 3.43 | 30 |
| 7 | fedratinib | 3.40 | 29 |
| 8 | gilteritinib | 3.40 | 29 |
| 9 | linifanib | 3.33 | 27 |
| 10 | at 7519 | 3.33 | 27 |
| 11 | jnj 7706621 | 3.09 | 21 |
| 12 | lestaurtinib | 3.04 | 20 |
| 13 | ruboxistaurin | 2.94 | 18 |
| 14 | r 406 | 2.83 | 16 |
| 15 | k 252a | 2.83 | 16 |
| 16 | pf 00562271 | 2.77 | 15 |
| 17 | bms 345541 | 2.71 | 14 |
| 18 | kw 2449 | 2.64 | 13 |
| 19 | gsk 690693 | 2.64 | 13 |
| 20 | ast 487 | 2.56 | 12 |
| 21 | zotiraciclib | 2.56 | 12 |
| 22 | rebastinib | 2.20 | 8 |
| 23 | enzastaurin | 2.08 | 7 |
| 24 | rg 547 | 2.08 | 7 |
| 25 | sra 737 | 1.95 | 6 |
| 26 | sel 120 free base | 1.95 | 6 |
| 27 | Sorafenib | 1.79 | 5 |
| 28 | Harmaline | 0.69 | 1 |
| 29 | sp600125 | 0.69 | 1 |
About MAPK15 as a Drug Target
MAPK15 (mitogen-activated protein kinase 15) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 29 compounds with documented MAPK15 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
MAPK15 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.